Market Overview

ImmunoGen Announces Dr. Charles Morris as New Chief Development Officer


ImmunoGen (NASDAQ: IMGN), a biotechnology company that develops
anticancer therapeutics using its Targeted Antibody Payload (TAP)
technology and antibody expertise, today announced the appointment of
Charles Morris, MB, ChB, MRCP as Executive Vice President and Chief
Development Officer, effective today. Dr. Morris will be responsible for
leading all aspects of product development, including regulatory, at
ImmunoGen. He reports to Daniel Junius, President and Chief Executive

“Charlie has extensive experience leading the strategic development and
registration of novel oncology compounds – expertise essential to
ImmunoGen with our advancing and expanding product pipeline,” commented
Mr. Junius. “We now have three wholly owned clinical-stage compounds,

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (IMGN)

View Comments and Join the Discussion!

Partner Center